Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., July 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on July 1, 2024 the Company granted inducement awards to purchase up to 124,000 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
美國馬薩諸塞州沃爾瑟姆，2024年7月5日/美通社/--Syndax Pharmaceuticals（納斯達克: SNDX） ，一家臨床階段的生物製藥公司，正在開發一系列創新的癌症治療方案。今天宣佈，在2023年引誘計劃下，公司於2024年7月1日向8名新員工授予期權，以購買高達124,000股普通股。股票期權將於四年內歸屬，其中基礎股份的25%將在歸屬開放日期的一週年紀念日上歸屬，並在此後36個月內每月歸屬1/48的基礎股份，前提是員工與Syndax繼續保持服務關係，直至適用的歸屬日期。
About Syndax
關於Syndax
Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax是一家臨床階段的生物製藥公司，正在開發一系列創新的抗癌治療藥物。該公司的產品管線包括高度選擇性Menin抑制劑revumenib和單克隆抗體axatilimab，該抗體可阻斷集落刺激因子1（CSF-1）受體。欲了解更多信息，請訪問 noted website 或在X（前身爲Twitter）和LinkedIn上關注該公司。
Syndax Contact
Syndax聯繫人
Sharon Klahre
Syndax Pharmaceuticals, Inc.
[email protected]
Tel 781.684.9827
Sharon Klahre
Syndax Pharmaceuticals，Inc.
[email protected]
電話 781.684.9827
SOURCE Syndax Pharmaceuticals, Inc.
消息來源：Syndax Pharmaceuticals，Inc。